Regenerative medicine has the potential to restore lost organ and tissue functions, and research on cell transplantation is steadily advancing toward clinical application. However, significant challenges remain in developing cell therapies for skeletal muscle, largely because the human body contains more than 600 individual muscles, making it impractical to treat all affected muscles through local transplantation alone. One strategy to overcome this limitation is to enhance the intrinsic regenerative capacity of muscle through various modalities; in this review, we define these approaches as pro-regenerative drugs. Histone deacetylase (HDAC) inhibitors provide a compelling example, demonstrating that stimulation of endogenous muscle regeneration can confer therapeutic benefits in the genetic disease Duchenne muscular dystrophy (DMD). This raises a fundamental question: why do pro-regenerative drugs provide durable benefits without Dystrophin restoration? This review summarizes the current status and importance of pro-regenerative drug development and discusses why sustained therapeutic effects can be achieved despite the lack of gene complementation. It also highlights key pathways that promote muscle regeneration as potential targets for future therapies.
Fukada, So-ichiro, Kubo, Atsushi, Kanagawa, Motoi et al. Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development. // Cell Regeneration. – 2026. – DOI: 10.1186/s13619-026-00296-8. – URL: https://www.biomedcentral.com/openurl?doi=10.1186/s13619-026-00296-8
Fukada, So-ichiro, Kubo, Atsushi, Kanagawa, Motoi, Aoki, & Yoshitsugu (2026). Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development. Cell Regeneration. https://doi.org/10.1186/s13619-026-00296-8
Fukada, et al. “Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development.” Cell Regeneration, 2026. doi:10.1186/s13619-026-00296-8.
@article{Fukada2026,
title = {Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development},
author = {Fukada and So-ichiro and Kubo and Atsushi and Kanagawa and Motoi and Aoki and Yoshitsugu},
journal = {Cell Regeneration},
year = {2026},
doi = {10.1186/s13619-026-00296-8},
url = {https://www.biomedcentral.com/openurl?doi=10.1186/s13619-026-00296-8}
}
Background Human liver organoids are useful for modeling steatotic liver injury and exploring disease-related mechanisms. This study examined the role of negative elongation factor E (NELFE) in metabolic dysfunction-associated steatotic...
Dysfunctional Epicardial adipose tissue (EAT), a specific beige/brown-like fat depot predominantly present in humans, is associated with coronary artery disease, atrial fibrillation and impaired systolic function. On the molecular...
Allometric growth is a key factor in understanding morphological development and biomass allocation in marine invertebrates. In crustaceans, growth is typically non-isometric, with mass scaling disproportionately with body size across...
The progression of malignancy depends entirely on profound restructuring of cells metabolic framework, allowing tumors to bypass physiological limitations while sustaining constant anabolic growth. Alteration of metabolic networks...
The discovery of induced pluripotent stem cells (iPSC) was met with optimism that this new technology would revolutionize how we model and treat human diseases. The last 20 years of research, however, has somewhat tempered the initial...